These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17942884)

  • 41. [Breast cancer and Her-2].
    Hatake K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144
    [No Abstract]   [Full Text] [Related]  

  • 42. [Medical, non-endocrine treatment of metastatic breast cancer--a status].
    Lindberg H; Nielsen DL; Kamby C
    Ugeskr Laeger; 2007 Apr; 169(17):1556-60. PubMed ID: 17484824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of trastuzumab.
    Vogel CL; Reddy JC; Reyno LM
    Cancer Res; 2005 Mar; 65(5):2044. PubMed ID: 15753405
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improving the efficacy of trastuzumab in breast cancer.
    Suzuki E; Toi M
    Cancer Sci; 2007 Jun; 98(6):767-71. PubMed ID: 17428260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The incidence and treatment outcome after radiotherapy for brain metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab.
    Arif S; Barrett-Lee PJ; Jordan C
    Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):719-20. PubMed ID: 17100160
    [No Abstract]   [Full Text] [Related]  

  • 48. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
    Burstein HJ; Winer EP
    J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
    [No Abstract]   [Full Text] [Related]  

  • 49. [Significance of HER2 testing in breast cancer].
    Ni YB; Yang WJ; Bu H; Zheng H
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):76-8. PubMed ID: 21426800
    [No Abstract]   [Full Text] [Related]  

  • 50. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimising the Role of Herceptin in Breast Cancer. Symposium proceedings. Monte Carlo, June 19-21, 2000.
    Oncology; 2001; 61 Suppl 2():1-91. PubMed ID: 11758500
    [No Abstract]   [Full Text] [Related]  

  • 52. 5. Tanstuzumab treatment for breast cancer.
    Hatake K; Tokudome N; Ito Y
    Intern Med; 2007; 46(3):149-50. PubMed ID: 17268136
    [No Abstract]   [Full Text] [Related]  

  • 53. Trastuzumab: mechanisms of resistance and therapeutic opportunities.
    Calabrich A; Fernandes Gdos S; Katz A
    Oncology (Williston Park); 2008 Oct; 22(11):1250-8; discussion 1259, 1263. PubMed ID: 18980023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 55. Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland.
    Ann Oncol; 2001; 12 Suppl 1():1-107. PubMed ID: 11816498
    [No Abstract]   [Full Text] [Related]  

  • 56. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast cancer--loss of PTEN predicts resistance to treatment.
    Pandolfi PP
    N Engl J Med; 2004 Nov; 351(22):2337-8. PubMed ID: 15564551
    [No Abstract]   [Full Text] [Related]  

  • 58. Trastuzumab beyond progression: a challenge to translational oncology?
    Santoro A; Gullo G
    Ann Oncol; 2010 Nov; 21(11):2131-2134. PubMed ID: 20732933
    [No Abstract]   [Full Text] [Related]  

  • 59. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER-2-positive breast cancer: hope beyond trastuzumab.
    Bartsch R; Wenzel C; Zielinski CC; Steger GG
    BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.